KNUSTSpace >
Conference Proceedings >
College of Health Sciences >

Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/14484

Title: The action of cryptolepine on prostate cancer cell lines.
Authors: Akwaboah, Emmanuella Appiah
Ansah, Charles
Keywords: Cryptolepine
Prostate Cancer
Issue Date: 22-Jul-2021
Abstract: Cryptolepine (CLP) is an alkaloid obtained from Cryptolepis sanguinolenta. CLP has shown activity on several cancer cell lines. However, its activity on prostate cancer cells has yet to be investigated. The present study involved the effect of cryptolepine on prostate cancer cell lines. Cryptolepine (20, 10, 5, 2.5 and 1.25 µM) showed a concentration-dependent decrease in cell viability in DU 145(cancer) and RWPE- 1(non-cancer) cell lines after 24 h and 48 h. The Selectivity indices (SI) were 3.054 and 2.263 for 24 h and 48 h respectively. In the Apoptosis/Necrosis Detection Assay, cell lines were treated with 10, 5 and 2.5 µM of CLP for 48 h. The percentage of viable cells decreased with increasing concentrations of the compound. However, the percentage of viable RWPE-1 cells were significantly more than DU 145 cells at the same concentrations with no evidence of necrotic cells. This proved the selectivity of CLP between cancer and non-cancer cell lines. To prove the type of apoptosis the cells underwent, the mitochondrial membrane potential was measured using the Rhodamine 123 assay. Consequently, there was a concentration-dependent decrease in the membrane potential with increasing concentrations of CLP suggesting the intrinsic pathway of apoptosis. Caspases are the executioners of apoptosis. The activities of caspase-3 and caspase-9 were measured. There was a concentration-dependent increase in the levels of caspases-3 and -9 up to 20 µM CLP. The expression of the genes PTEN (tumour suppressor gene), PDHA1, C-MYC, AKTv2, SREBP 1 and 2 (oncogenes) was assessed using RT-qPCR. There was an increase in the expression of the tumour suppressor gene PTEN and a relative decrease in the expression of the oncogenes. The results showed that CLP has a potential as a candidate agent in prostate cancer management
Description: A thesis submitted in partial fulfillment of the requirements for the Degree of Master of Philosophy (Pharmacology) in the Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences.. October, 2019
URI: http://hdl.handle.net/123456789/14484
Appears in Collections:College of Health Sciences

Files in This Item:

File Description SizeFormat
Akwaboah Emmanuella Appiah.pdf1.75 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback